BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, July 26, 2026
Home » Topics » Analysis and data insight, BioWorld

Analysis and data insight, BioWorld
Analysis and data insight, BioWorld RSS Feed RSS

Strategy compass

Bio Korea 2026: US policy risks shift to execution framework

May 4, 2026
By Marian (YoonJee) Chu
No Comments
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies can tailor regulatory strategies early, and across the entire development cycle.
Read More

Biggest gainers and losers for April 27-May 1, 2026

May 4, 2026
The top 10 biopharma stock gainers and losers for the week.
Read More

Biopharma money raised: Jan. 1-April 30, 2026

May 1, 2026
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma

May 1, 2026
Total raised in public, private and other financings of biopharma companies, comparing 2019-2026.
Read More
Financial graph
Index insights

Day One buyout headlines active Q1 for cancer stocks

April 30, 2026
By Amanda Lanier
No Comments
After a standout 2025, the BioWorld Cancer Index (BCI) started 2026 on more measured footing. Early volatility this year saw the BCI drop 11.51% by the end of January before recovering to post a modest 1.39% gain for the first quarter (Q1).
Read More
AI generated image for researcher developing antisense oligonucleotides

Bio Korea 2026 kicks off with spotlight on oligonucleotides

April 29, 2026
By Marian (YoonJee) Chu
No Comments
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and the promise of “programmable,” precision medicine for patients, speakers at Bio Korea 2026 said April 28.
Read More
U.S. Capitol building

US legislative reforms needed to make biosimilars competitive

April 27, 2026
By Mari Serebrov
No Comments
Now that the FDA is on board with doing away with the U.S.’ unique two-tier biosimilar pathway, the biosimilar industry is urging Congress to pass the bipartisan Biosimilar Red Tape Elimination Act, which would recognize that biosimilars and interchangeables are one and the same.
Read More

Biggest gainers and losers for April 20-24, 2026

April 27, 2026
The top 10 biopharma stock gainers and losers for the week.
Read More

Biopharma money raised: Jan. 1-April 23, 2026

April 24, 2026
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma

April 24, 2026
Total raised in public, private and other financings of biopharma companies, comparing 2019-2026.
Read More
Previous 1 2 … 7 8 9 10 11 12 13 14 15 … 247 248 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 24, 2026.
  • Cell nucleus architecture

    4D Nucleome opens new wave of gene regulation research, discovery

    BioWorld
    After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
  • Drug capsule spilling onto brain

    Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

    BioWorld Science
    Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
  • Business pipeline illustration

    Transcripta Bio raises funding to advance neuro pipeline

    BioWorld Science
    Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...
  • Other news to note for July 22, 2026

    BioWorld
    Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing